{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T09:58:39Z","timestamp":1784973519626,"version":"3.55.0"},"reference-count":26,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":4064,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2000,12]]},"abstract":"<jats:p><jats:bold>Study Objective.<\/jats:bold> To compare rates of adverse events with filgrastim versus sargramostim when given prophylactically to patients receiving myelosuppressive chemotherapy.<\/jats:p><jats:p><jats:bold>Design.<\/jats:bold> Retrospective review with center crossover.<\/jats:p><jats:p><jats:bold>Setting.<\/jats:bold> Ten United States outpatient chemotherapy centers.<\/jats:p><jats:p><jats:bold>Patients.<\/jats:bold> Four hundred ninety patients treated for lung, breast, lymphatic system, or ovarian tumors.<\/jats:p><jats:p><jats:bold>Intervention.<\/jats:bold> Prophylactic use of filgrastim or sargramostim, with dosages at investigator discretion.<\/jats:p><jats:p><jats:bold>Measurements and Main Results.<\/jats:bold> The frequency and severity of adverse events and the frequency of switching to the alternative CSF were assessed. There was no difference in infectious fever. Fever unexplained by infection was more common with sargramostim (7% vs 1%, p&lt;0.001), as were fatigue, diarrhea, injection site reactions, other dermatologic disorders, and edema (all p&lt;0.05). Skeletal pain was more frequent with filgrastim (p=0.06). Patients treated with sargramostim switched to the alternative agent more often (p&lt;0.001).<\/jats:p><jats:p><jats:bold>Conclusion.<\/jats:bold> Adverse events were less frequent with filgrastim than with sargramostim, suggesting that quality of life and treatment costs also may differ.<\/jats:p>","DOI":"10.1592\/phco.20.19.1432.34861","type":"journal-article","created":{"date-parts":[[2004,6,15]],"date-time":"2004-06-15T15:22:20Z","timestamp":1087312940000},"page":"1432-1440","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Comparative Safety of Filgrastim versus Sargramostim in Patients Receiving Myelosuppressive Chemotherapy"],"prefix":"10.1002","volume":"20","author":[{"given":"Gary","family":"Milkovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J.","family":"Moleski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Reitan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Dunning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene A.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Paivanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Wyant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Jake","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1200\/JCO.1994.12.11.2471","article-title":"Recommendations for the use of hematopoietic colony\u2010stimulating factors: evidence\u2010based, clinical practice guidelines","volume":"12","author":"American Society for Clinical Oncology.","year":"1994","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00009894"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1177\/001857879903400305","article-title":"A medication use evaluation of adverse events associated with colony\u2010stimulating factors","volume":"34","author":"Rotella DL","year":"1999","journal-title":"Hosp Pharm"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/513857"},{"key":"e_1_2_1_6_2","first-page":"927","article-title":"Drug formulary review process for sargramostim and filgrastim: focus on analysis of adverse drug reactions","volume":"15","author":"Kellihan MJ","year":"1993","journal-title":"Clin Ther"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199107183250305"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.6.1430.1430"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910715)68:2<441::AID-CNCR2820680239>3.0.CO;2-4"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-110-12-976"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-109-10-789"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.10.2496.2496"},{"key":"e_1_2_1_13_2","first-page":"55","article-title":"Feasibility of adjuvant dose\u2010intensive cyclophosphamide with G\u2010CSF after doxorubicin in women with high\u2010risk stage II\/III resectable breast cancer [abstr]","volume":"11","author":"Hudis C.","year":"1992","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-12-996"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)81918-3"},{"issue":"8591","key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0140-6736(88)91771-0","article-title":"Recombinant human granulocyte\u2010macrophage colony\u2010stimulating factor produces fever [letter]","volume":"1","author":"Peters WP","year":"1998","journal-title":"Lancet"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.9.1460"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198712173172501"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood.V73.1.31.31","article-title":"Recombinant human granulocyte\u2010macrophage colony\u2010stimulating factor in patients with myelodysplastic syndromes: a phase I\/II trial","volume":"73","author":"Ganser A.","year":"1989","journal-title":"Blood"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.1.245.245"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1200\/JCO.1996.14.11.2976","article-title":"Randomized double\u2010blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate\u2010dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer","volume":"14","author":"Jones SE","year":"1996","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_22_2","first-page":"19","article-title":"Clinical properties of yeast\u2010derived versus Escherichia coli\u2010derived granulocyte\u2010macrophage colony\u2010stimulating factor","volume":"15","author":"Dorr RT","year":"1993","journal-title":"Clin Ther"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.V74.8.2634.2634","article-title":"Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte\u2010macrophage colony\u2010stimulating factor","volume":"74","author":"Lieschke GJ","year":"1989","journal-title":"Blood"},{"key":"e_1_2_1_24_2","first-page":"5","article-title":"International drug monitoring. The role of the hospital","volume":"425","author":"World Health Organization.","year":"1969","journal-title":"WHO Tech Rep Ser"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(93)90376-Q"},{"key":"e_1_2_1_26_2","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood.V82.8.2329.2329","article-title":"Randomized, double\u2010blind, placebo\u2010controlled phase III study of recombinant human granulocyte\u2010macrophage colony\u2010stimulating factor as adjunct to induction treatment of high\u2010grade malignant non\u2010Hodgkin's lymphomas","volume":"82","author":"Gerhartz HH","year":"1993","journal-title":"Blood"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.6.929"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.20.19.1432.34861","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.20.19.1432.34861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:53:11Z","timestamp":1761047591000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.20.19.1432.34861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2000,12]]}},"alternative-id":["10.1592\/phco.20.19.1432.34861"],"URL":"https:\/\/doi.org\/10.1592\/phco.20.19.1432.34861","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,12]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}